鱼跃医疗(002223) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 1,821,064,321.07, representing a 9.60% increase compared to CNY 1,661,551,525.50 in the same period last year[4] - Net profit attributable to shareholders was CNY 464,412,551.72, a slight increase of 1.11% from CNY 459,300,986.21 year-on-year[4] - Net profit for Q1 2022 was CNY 461,879,861.40, slightly up from CNY 461,824,942.88 in Q1 2021, indicating a stable performance[17] - Basic and diluted earnings per share for Q1 2022 were both CNY 0.4634, up from CNY 0.4582 in Q1 2021[18] Cash Flow - The net cash flow from operating activities surged by 138.89% to CNY 411,916,788.95, compared to CNY 172,429,602.22 in the previous year[4] - Cash flow from operating activities was CNY 1,614,206,082.98, compared to CNY 1,409,954,354.58 in the same period last year, indicating improved cash generation[19] - The net cash flow from operating activities for Q1 2022 was CNY 411,916,788.95, an increase from CNY 172,429,602.22 in Q1 2021, representing a growth of approximately 139.5%[20] - Cash inflow from financing activities totaled CNY 200,000,000.00, a significant decrease from CNY 956,743,000.00 in Q1 2021, reflecting a decline of about 79.1%[21] - The net cash flow from financing activities was CNY 121,162,300.69, compared to -CNY 36,716,522.70 in the previous year, showing a turnaround in cash flow[21] Assets and Liabilities - The company's total assets grew by 5.37% to CNY 12,641,855,270.31 from CNY 11,997,858,899.82 at the end of the previous year[4] - The total liabilities as of Q1 2022 were CNY 3,797,436,887.08, an increase from CNY 3,568,221,107.80 in the previous year[17] - The total current liabilities stood at approximately RMB 1.87 billion, compared to RMB 1.83 billion at the beginning of the year, reflecting a slight increase of about 2.1%[14] - Long-term borrowings increased to RMB 1.65 billion from RMB 1.46 billion, indicating a growth of approximately 13.2%[14] Investments and Expenses - Research and development expenses increased by 78.62% compared to the same period last year, indicating a significant investment in innovation[7] - Research and development expenses increased significantly to CNY 129,004,920.41, compared to CNY 72,224,167.63 in the previous year, reflecting a focus on innovation[17] - The company reported a 240.99% increase in investment income compared to the previous year, attributed to dividends received from affiliated fund companies[7] - Cash paid for investment activities was CNY 3,797,238,000.00, compared to CNY 2,953,000,000.00 in Q1 2021, reflecting an increase of about 28.5%[20] Equity and Shareholder Information - The total equity attributable to shareholders of the parent company reached CNY 8,737,427,633.72, up from CNY 8,272,114,352.19 year-over-year[17] - The company repurchased a total of 12,852,383 shares, accounting for 1.28% of the total share capital, with a total transaction amount of approximately RMB 364.91 million[11] - The company's total equity remains stable, with no significant changes reported in the equity section of the balance sheet[14] Government Support - The company received government subsidies amounting to CNY 45,417,921.51, contributing to the increase in other income by 305.43% year-on-year[6] Future Outlook - The company plans to continue its market expansion and product development strategies to enhance its competitive position in the medical equipment sector[12]